Fundraising Fox
Armis Biopharma
Fort Collins, US · Delaware corporation
Find your way into Armis Biopharma
Sign up to see every warm intro you have to Armis Biopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Armis Biopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Armis Biopharma develops targeted antimicrobial therapies designed to treat and prevent localized, drug-resistant infections by delivering medications locally to increase efficacy and reduce systemic toxicity.
Founders & leadership
SC
Steve CoderChief Financial OfficerSteve Coder is an executive with over 20 years of experience in general management, manufacturing, finance, and operations, with background in M&A, product development, and strategic business direction. He serves as Executive Officer and Director at Armis Biopharma, which develops targeted antimicrobial therapies to treat drug-resistant infections.
MV
Michael VossChief Executive OfficerHe has held leadership roles in research and development, sales, marketing, and operations across pre-revenue startups and established medical device and healthcare companies, and holds a patent related to pleural effusion treatment technology.
RK
Robert KaliExecutive
DT
Dennis TemplarExecutive
MH
Michael HandleyChief Executive Officer & Director2012–2018Michael Handley has over 25 years of experience in life sciences and holds leadership positions including CEO of Valion Bio and President of Velocity Bioworks, with background spanning multiple therapeutic areas and business functions.
Board
AR
Alan RuudBoard director
TZ
Theodore ZiemannBoard director
WN
William Nelson, MD, Ph.D.Board director
ML
Michael LitwackBoard director
AS
Alan Smith, Ph.D.Board director
CR
Christopher RuddBoard director
WN
William Nelson, VBoard director
Reported raises · per SEC filings
Form D private placements$21.2M disclosed across 8 rounds · 2014–2025
▶$1MraisedJul 2025 · 1 investors · Other Health CareRule 506(b)
▶$1MraisedJul 2025 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Theodore ZiemannDirector
- Alan RuudDirector
- Steve CoderExecutive Officer, Director
- Michael VossExecutive Officer, Director
- William Nelson, MD, Ph.D.Director
- Michael LitwackDirector
- Alan Smith, Ph.D.Director
- Christopher RuddDirector
- Offering amount
- $3M
- Amount sold
- $1M
- Proceeds to insiders
- $150K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.3MraisedSep 2022 · 14 investors · Other Health CareRule 506(b)
▶$7.3MraisedSep 2022 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ted ZiemannExecutive Officer, Director
- William Nelson, MD. Ph.D.Director
- Ed Neas, Ph.D.Director
- Michael LitwackDirector
- Steve CoderExecutive Officer, Director
- Christopher RuudExecutive Officer, Director
- Alan Smith, Ph.D.Director
- Alan RuudDirector
- Offering amount
- $10M
- Amount sold
- $7.3M
- First sale
- May 2020
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1.8MraisedSep 2018 · 19 investors · Other Health CareRule 506(b)
▶$1.8MraisedSep 2018 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen CoderDirector
- William NelsonDirector
- Michael LitwackDirector
- Robert KaliExecutive Officer
- Ted ZiemannExecutive Officer, Director
- Alan SmithDirector
- Ed NeasDirector
- Dennis TemplarExecutive Officer, Director
- Alan RuudDirector
- Offering amount
- $10M
- Amount sold
- $1.8M
- Sales commissions
- $490.1K
- Placement agents
- Arete Wealth Management, LLC
- First sale
- Jun 2018
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$2.7MraisedNov 2017 · 7 investors · Other Health CareRule 506(b)
▶$2.7MraisedNov 2017 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ed NeasExecutive Officer, Director
- William NelsonDirector
- Michael HandleyExecutive Officer, Director
- Dennis TemplarExecutive Officer, Director
- Robert KaliExecutive Officer
- Stephen CoderDirector
- Alan RuudDirector
- Alan SmithDirector
- Ted ZiemannExecutive Officer, Director
- Michael LitwackDirector
- Offering amount
- $14M
- Amount sold
- $2.7M
- Sales commissions
- $840K
- Placement agents
- TORREYA CAPITAL, CG CAPITAL MARKETS LLC, PRECISION SECURITIES, LLC
- First sale
- Feb 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$125KraisedNov 2017 · 1 investors · Other Health CareRule 506(b)
▶$125KraisedNov 2017 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Michael LitwackDirector
- Stephen CoderDirector
- William NelsonDirector
- Alan RuudDirector
- Michael HandleyExecutive Officer, Director
- Robert KaliExecutive Officer
- Dennis TemplarExecutive Officer, Director
- Alan SmithDirector
- Ed NeasExecutive Officer, Director
- Ted ZiemannExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $125K
- Sales commissions
- $1.8M
- Placement agents
- APPLIED CAPITAL, LLC, PRECISION SECURITIES, LLC
- First sale
- Oct 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$3.3MraisedJun 2016 · 16 investors · Other Health CareRule 506(b)
▶$3.3MraisedJun 2016 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William Nelson, VDirector
- Roy Carver, Jr.Director
- Stephen CoderDirector
- Alan SmithDirector
- Ted ZiemannExecutive Officer, Director
- Loretta MealyDirector
- Dennis TemplarExecutive Officer, Director
- Alan RuudDirector
- Ed NeasDirector
- Michael HandleyExecutive Officer, Director
- Michael LitwackDirector
- Robert KaliExecutive Officer
- Offering amount
- $5.8M
- Amount sold
- $3.3M
- Sales commissions
- $203.6K
- Placement agents
- DONENFELD, ALAN PAUL
- First sale
- Jan 2016
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1.7MraisedFeb 2016 · 19 investors · Other Health CareRule 506(b)
▶$1.7MraisedFeb 2016 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert KaliExecutive Officer
- Michael LitwackDirector
- William Nelson, VDirector
- Dennis TemplarExecutive Officer, Director
- Doug CoderDirector
- Alan SmithDirector
- Ted ZiemannDirector
- Ed NeasDirector
- Roy, Jr. CarverDirector
- Michael HandleyExecutive Officer, Director
- Loretta MealyDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Mar 2015
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$3.2MraisedApr 2014 · 20 investors · OtherRule 506(b)
▶$3.2MraisedApr 2014 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Roy, Jr. CarverDirector
- Michael HandleyExecutive Officer
- Doug CoderDirector
- Ted ZiemannDirector
- Michael LitwackDirector
- Dennis TemplarExecutive Officer, Director
- Robert KaliExecutive Officer
- Ed NeasDirector
- Alan SmithDirector
- Cathy SohnDirector
- Loretta MealyDirector
- Offering amount
- $3.2M
- Amount sold
- $3.2M
- First sale
- Feb 2014
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Amicus TherapeuticsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
IRIS MEDICINEIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.
Companies working in the same space as Armis Biopharma.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $694.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Armis Biopharma do?
- Armis Biopharma develops targeted antimicrobial therapies designed to treat and prevent localized, drug-resistant infections by delivering medications locally to increase efficacy and reduce systemic toxicity.
- How much funding has Armis Biopharma raised?
- Armis Biopharma has disclosed $21.2M raised across 8 rounds.
- Where is Armis Biopharma headquartered?
- Armis Biopharma is headquartered in Fort Collins, US.